Taysha Gene Therapies, Inc.TSHA
Price (close)
$4.79
Market cap
$1.6B
P/E
—
Revenue (TTM)
$5.5M
Net income
-$149.6M
Dividend yield
—
1-year total return
56.5%
Net margin
-2728.0%
Revenue growth
-32.3%
Debt / equity
0.13x
What Taysha Gene Therapies, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $2.5M | $15.5M | $8.3M | $9.8M |
| Net income | -$60.0M | -$174.5M | -$166.0M | -$111.6M | -$89.3M | -$109.0M |
| Free cash flow | -$30.8M | -$132.3M | -$109.0M | -$76.9M | -$81.6M | -$93.8M |
More on TSHA.
- Taysha Gene Therapies, Inc. summary
- Taysha Gene Therapies, Inc. financial statements
- Taysha Gene Therapies, Inc. key metrics
- Taysha Gene Therapies, Inc. health scores and style box
- Taysha Gene Therapies, Inc. earnings
- Taysha Gene Therapies, Inc. dividends
- Taysha Gene Therapies, Inc. valuation
- Taysha Gene Therapies, Inc. ownership and insiders
- Taysha Gene Therapies, Inc. peers
Figures from Taysha Gene Therapies, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.